GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
37.32
-0.18 (-0.48%)
Apr 25, 2025, 12:02 PM EDT - Market open
GSK Revenue
In the year 2024, GSK had annual revenue of 31.38B GBP with 3.46% growth. GSK had revenue of 8.12B in the quarter ending December 31, 2024, with 0.81% growth.
Revenue (ttm)
31.38B GBP
Revenue Growth
+3.46%
P/S Ratio
1.91
Revenue / Employee
457,183 GBP
Employees
68,629
Market Cap
75.13B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
GSK News
- 4 days ago - LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed - FXEmpire
- 8 days ago - UK approves combination therapies of GSK's blood cancer drug Blenrep - Reuters
- 8 days ago - Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease - GlobeNewsWire
- 8 days ago - AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices - Business Wire
- 8 days ago - GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices - Business Wire
- 10 days ago - GSK in breach for misleading prescribing information on Omjjara, industry body says - Reuters
- 10 days ago - Trump says US pharma tariffs coming in not-too-distant future - Reuters
- 14 days ago - Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages - CNBC